BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Pfizer Inc. (PFE)'s Arthritis Pill Tofacitinib Matches Abbott Laboratories (ABT)'s Humira in Final Studies


9/8/2011 7:03:59 AM

Pfizer Inc. (PFE)’s experimental pill for rheumatoid arthritis was as effective as Humira from Abbott Laboratories (ABT) and showed no new side effects in study results the company plans to submit for U.S. approval this year. Nine study summaries were released today and will be presented at the American College of Rheumatology conference in Chicago in November. In one trial, both doses of Pfizer’s drug, called tofacitinib, were slightly more effective than Humira across six categories of improvement in symptoms and patient mobility, though the study wasn’t big enough to establish the pill’s superiority.

Read at BioSpace.com
Read at Bloomberg
Read at Reuters

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->